Compounds > clopidogrel

clopidogrel and elinogrel

clopidogrel has been researched along with elinogrel in 19 studies

Research

Studies (19)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	18 (94.74)	24.3611
2020's	1 (5.26)	2.80

Authors

Authors	Studies
Chen, B; Danon, JJ; Kassiou, M; Ma, BB; Montgomery, AP	1
Antonino, MJ; Bliden, KP; Conley, PB; Gretler, DD; Gurbel, PA; Jurek, MM; Pakyz, RE; Shuldiner, AR; Stephens, G; Tantry, US	1
Cattaneo, M; Podda, GM	1
Bhatt, DL; Gibson, CM; Gretler, DD; Harrington, RA; Huber, K; Kochman, J; Leonardi, S; Madan, M; McClure, MW; Paynter, GE; Rao, SV; Roe, MT; Thompson, V; Welsh, RC; Zeymer, U	1
Barthélémy, O; Bellemain-Appaix, A; Beygui, F; Brieger, D; Cayla, G; Collet, JP; Montalescot, G; Pena, A; Silvain, J	1
White, HD	1
Cattaneo, M	1
Storey, RF	1
Moliterno, DJ; Rajan, L	1
Andre, P; Conley, PB; Haberstock-Debic, H; Mills, S; Phillips, DR	1
Contractor, H; Ruparelia, N	1
Angiolillo, DJ; Broderick, S; Buerke, M; Conley, PB; Dabrowski, M; Gurbel, PA; Harrington, RA; Jennings, LK; Kochman, J; McClure, MW; Neumann, FJ; Rao, SV; Saucedo, JF; Stephens, G; Stumpf, J; Trenk, D; Welsh, RC; Wójcik, J	1
Angiolillo, DJ; Berdan, LG; Bhatt, DL; French, WJ; Gibson, CM; Gretler, DD; Gurbel, PA; Harrington, RA; Huber, K; Kochman, J; Leonardi, S; Madan, M; McClure, MW; Paynter, G; Rao, SV; Thompson, VP; Welsh, RC; Zeymer, U	1
Montalescot, G; Silvain, J	1
Barn, K; Steinhubl, SR	1
Bernlochner, I; Sibbing, D	1
DiNicolantonio, JJ; Serebruany, VL; Sibbing, D	1
Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ	1
Caldeira, D; Ferreira, JJ; Pinto, FJ	1

Reviews

12 review(s) available for clopidogrel and elinogrel

Article	Year
Strategies for targeting the P2Y Bioorganic & medicinal chemistry letters, 2022, 09-01, Volume: 71 Topics: Central Nervous System; Ligands; Microglia; Platelet Aggregation; Receptors, Purinergic P2Y12; Signal Transduction	2022
State of the art of new P2Y12 antagonists. Internal and emergency medicine, 2010, Volume: 5, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine	2010
New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. Journal of the American College of Cardiology, 2010, Nov-02, Volume: 56, Issue:19 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Postoperative Complications; Purinergic P2 Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Sulfonamides; Ticlopidine	2010
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1 Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine	2011
Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1 Topics: Adenosine; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Protein Binding; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2011
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS? Current cardiology reports, 2011, Volume: 13, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine	2011
Advances in antiplatelet therapy for acute coronary syndromes. Postgraduate medical journal, 2012, Volume: 88, Issue:1041 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
A brief review of the past and future of platelet P2Y12 antagonist. Coronary artery disease, 2012, Volume: 23, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2012
Thienopyridines and other ADP-receptor antagonists. Handbook of experimental pharmacology, 2012, Issue:210 Topics: Adenosine; Adenosine Monophosphate; Animals; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine	2012
Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond. Cardiology, 2014, Volume: 127, Issue:1 Topics: Acute Lung Injury; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Dyspnea; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Sulfonamides; Ticagrelor; Ticlopidine; Transfusion Reaction	2014
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. Atherosclerosis, 2014, Volume: 233, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine	2014
Dyspnea and reversibility profile of P2Y₁₂ antagonists: systematic review of new antiplatelet drugs. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:4 Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Dyspnea; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine	2014

Trials

4 trial(s) available for clopidogrel and elinogrel

Article	Year
The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C192 genotype: first experience in patients. Journal of thrombosis and haemostasis : JTH, 2010, Volume: 8, Issue:1* Topics: Adenosine Diphosphate; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Coagulation; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Collagen; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Humans; Male; Microfilament Proteins; Middle Aged; Phenotype; Phosphoproteins; Phosphorylation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Purinergic P2 Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Sulfonamides; Thrombelastography; Ticlopidine	2010
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous American heart journal, 2010, Volume: 160, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Tolerance; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Ticlopidine; Time Factors; Treatment Outcome; Troponin; Young Adult	2010
Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (I Circulation. Cardiovascular interventions, 2012, Volume: 5, Issue:3 Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Canada; Clopidogrel; Double-Blind Method; Drug Administration Schedule; Europe; Female; Heart Diseases; Humans; Injections, Intravenous; Male; Middle Aged; Models, Statistical; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Ticlopidine; Treatment Outcome; United States	2012
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PC Circulation. Cardiovascular interventions, 2012, Volume: 5, Issue:3 Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Canada; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Europe; Female; Heart Diseases; Hemorrhage; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stroke; Sulfonamides; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; United States	2012

Other Studies

3 other study(ies) available for clopidogrel and elinogrel

Article	Year
Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. American heart journal, 2011, Volume: 161, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Lactones; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyridines; Quinazolinones; Randomized Controlled Trials as Topic; Receptor, PAR-1; Sulfonamides; Ticagrelor; Ticlopidine	2011
A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist. The Journal of pharmacology and experimental therapeutics, 2011, Volume: 339, Issue:1 Topics: Animals; Clopidogrel; Cyclic AMP; Fibrinolytic Agents; Humans; Mice; Mice, Inbred C57BL; Mice, Knockout; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Agonists; Purinergic P2Y Receptor Antagonists; Quinazolinones; Radioligand Assay; Receptors, Purinergic P2Y12; Sulfonamides; Thrombosis; Ticlopidine	2011
Rapid P2Y12 inhibition: still an unmet medical need. Circulation. Cardiovascular interventions, 2012, Volume: 5, Issue:3 Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Female; Heart Diseases; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Ticlopidine	2012